Abbonarsi

Rationale and design of the SMall Annuli Randomized To Evolut or SAPIEN Trial (SMART Trial) - 26/11/21

Doi : 10.1016/j.ahj.2021.09.011 
Howard C. Herrmann, MD a, , Mohamed Abdel-Wahab, MD b, Guilherme F. Attizzani, MD c, Wayne Batchelor, MD d, Sabine Bleiziffer, MD e, Sarah Verdoliva, MS f, Yanping Chang, MS f, Hemal Gada, MD, MBA g, Linda Gillam, MD, MPH h, Mayra Guerrero, MD i, Paul D. Mahoney, MD j, Anna Sonia Petronio, MD k, Toby Rogers, MD l, m, Joshua Rovin, MD n, Molly Szerlip, MD o, Brian Whisenant, MD p, Roxana Mehran, MD q, Didier Tchetche, MD r
a Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 
b Heart Center Leipzig at the University of Leipzig, Leipzig, Germany 
c University Hospitals of Cleveland, Cleveland, OH 
d Inova Heart and Vascular Institute, Falls Church, VA 
e Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany 
f Medtronic, Mounds View, MN 
g UPMC Harrisburg, Harrisburg, PA 
h Morristown Medical Center/Atlantic Health System, Morristown, NJ 
i Mayo Clinic, Rochester, MN 
j Sentara Healthcare, Norfolk, VA 
k Università di Pisa, Ospedale di Cisanello Pisa, Italy 
l MedStar Washington Hospital Center, Washington, DC 
m National Institutes of Health, Bethesda, MD 
n BayCare Health System/Morton Plant Hospital, Clearwater, FL 
o Baylor Scott and White Heart Hospital, Plano, TX 
p Intermountain Medical Center, Murray, UT 
q Mount Sinai School of Medicine, New York, NY 
r Clinique Pasteur, Toulouse, France 

Reprint requests: Howard C. Herrmann, MD, Hospital of the University of Pennsylvania, PCAM South Pavilion 11-107, 3400 Civic Center Boulevard, Philadelphia, PA 19104.Hospital of the University of PennsylvaniaPCAM South Pavilion 11-107, 3400 Civic Center BoulevardPhiladelphiaPA19104

Riassunto

Background

The SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial was designed to compare the performance of the two most widely available commercial transcatheter aortic valve replacement (TAVR) devices in patients with symptomatic severe native aortic stenosis with a small aortic valve annulus undergoing transfemoral TAVR. Patients with small aortic valve annuli are typically female and are often underrepresented in clinical trials.

Methods

The SMART Trial is an international, prospective, multi-center, randomized controlled, post-market trial. The trial will be conducted in approximately 700 subjects at approximately 90 sites globally. Inclusion criteria include severe aortic stenosis, aortic valve annulus area of ≤430 mm2 based on multi-detector computed tomography, and appropriate anatomy for both the Medtronic Evolut PRO/PRO+ self-expanding and Edwards SAPIEN 3/3 Ultra balloon-expandable devices. The primary clinical outcome composite endpoint is defined as mortality, disabling stroke or heart failure rehospitalization at 12 months. The co-primary valve function composite endpoint is defined as bioprosthetic valve dysfunction at 12 months which includes hemodynamic structural valve dysfunction, defined as a mean gradient ≥20 mmHg, non-structural valve dysfunction, defined as severe prothesis-patient mismatch or ≥moderate aortic regurgitation, thrombosis, endocarditis, and aortic valve re-intervention. Powered secondary endpoints will be assessed hierarchically.

Conclusions

The SMART trial will be the largest head-to-head comparative trial of transfemoral TAVR using the two most widely available contemporary TAVR devices in the setting of small aortic annuli and the largest trial to enroll primarily women.

Clinical trial registration

URL: www.clinicaltrials.gov, Unique identifier: NCT04722250.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Aortic stenosis, Prothesis-patient mismatch (PPM), Randomized trial, Transcatheter aortic valve replacement (TAVR)


Mappa


© 2021  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 243

P. 92-102 - Gennaio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • The NHLBI Study on Long-ter Otcomes after the Multisystem nflammatory yndrome n hildren (MUSIC): Design and Objectives
  • Dongngan T. Truong, Felicia L. Trachtenberg, Gail D. Pearson, Audrey Dionne, Matthew D. Elias, Kevin Friedman, Kerri H. Hayes, Lynn Mahony, Brian W. McCrindle, Matthew E. Oster, Victoria Pemberton, Andrew J. Powell, Mark W. Russell, Lara S. Shekerdemian, Mary Beth Son, Michael Taylor, Jane W. Newburger, for the MUSIC Study Investigators (Supplement 1), Audrey Dionne, Matthew D. Elias, Therese M. Giglia, Kimberly E. McHugh, Andrew M. Atz, Scott A. Pletzer, Dongngan T. Truong, Mark W. Russell, Sean M. Lang, R. Mark Payne, Jyoti K. Patel, Matthew?E. Oster, Lara S. Shekerdemian, Ricardo H. Pignatelli, Kristen Sexson, Brian W. McCrindle, Christopher Lam, Andreea Dragulescu, Rae SM Young, Beth Gamulka, Anita Krishnan, Brett R. Anderson, Kanwal M. Farooqi, Divya Shakti, Aimee S. Parnell, Onyekachukwu J Osakwe, Michelle C. Sykes, Lerraughn Morgan, Carl Y. Owada, Daniel Forsha, Michael R. Carr, Kae Watanabe, Michael A. Portman, Kristen B. Dummer, Jane C. Burns, Adriana H. Tremoulet, Kavita Sharma, Pei-Ni Jone, Michelle Hite Heather Heizer, Keren Hasbani, Shubhika Srivastava, Elizabeth C Mitchell, Camden L. Hebson, Jacqueline R. Szmuszkovicz, Pierre C. Wong, Andrew L. Cheng, Jodie K. Votava-Smith, Shuo Wang, Sindhu Mohandas, Gautam K. Singh, Sanjeev Aggarwal, Yamuna Sanil, Tamara T. Bradford, Juan Carlos G. Muniz, Jennifer S. Li, Michael Jay Campbell, Stephanie S. Handler, J Ryan Shea, Timothy M. Hoffman, Wayne J. Franklin, Arash A. Sabati, Todd T. Nowlen, Maryanne Chrisant
| Articolo seguente Articolo seguente
  • The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries
  • Alfredo E. Farjat, Saverio Virdone, Laine E. Thomas, Ajay K. Kakkar, Karen S. Pieper, Jonathan P. Piccini

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.